Merck & Co., Inc. (NYSE:MRK) Shares Down 1.9% – Time to Sell?

Posted by George Bondi on Sep 10th, 2026

Merck & Co., Inc. (NYSE:MRK – Get Free Report) shares fell 1.9% during trading on Thursday . The stock traded as low as $144.10 and last traded at $144.6840. Approximately 7,442,642 shares changed hands during trading, a decline of 31% from the average daily volume of 10,754,442 shares. The stock had previously closed at $147.53.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Analyst price-target increases signal confidence. HSBC raised its target from $150 to $172 and assigned a “buy” rating, while Guggenheim lifted its target to $170. Leerink Partners also increased its target from $127 to $161 and upgraded its view to “outperform.” These revisions suggest analysts see additional value in MRK’s pipeline and business outlook. Guggenheim increases Merck price target
Positive Sentiment: Merck is pursuing new oncology growth opportunities. The company is pairing antibody-drug conjugates (ADCs) with Keytruda in women’s cancers, a strategy intended to improve treatment options and build replacement revenue as Keytruda approaches patent expiration. Merck pairs ADCs with Keytruda
Neutral Sentiment: Investor attention remains elevated. Zacks highlighted MRK as one of the stocks attracting significant user interest, but the report does not identify a new fundamental catalyst. Merck’s recent Wells Fargo healthcare-conference presentation may provide additional insight into pipeline progress and strategy. Zacks Merck investor attention report
Negative Sentiment: Keytruda concentration remains the central risk. Although the ADC strategy is a potential long-term offset, investors may remain cautious about how quickly Merck can replace revenue and earnings threatened by the blockbuster drug’s patent expiration. That concern may be weighing on the stock despite bullish analyst targets.

Analysts Set New Price Targets

A number of research analysts have weighed in on MRK shares. Wolfe Research raised their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Argus raised their price target on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. Scotiabank boosted their price target on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. Finally, Bank of America upped their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Seventeen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $151.32.

Read Our Latest Stock Analysis on MRK

Merck & Co., Inc. Stock Performance

The firm’s 50 day moving average price is $135.91 and its two-hundred day moving average price is $124.10. The firm has a market cap of $356.96 billion, a PE ratio of 115.75, a PEG ratio of 6.46 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the company earned $2.13 EPS. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Insiders Place Their Bets

In related news, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter worth approximately $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

(Get Free Report)

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.